Want to see SE:ACE full AI Analyst Report?
ACE Stock Chart & Stats
kr3.17
-kr0.11(-3.47%)
At close: 4:00 PM EST
kr3.17
-kr0.11(-3.47%)
Day’s Range― - ―
52-Week Rangekr0.70 - kr5.23
Previous CloseN/A
Volume171.87K
Average Volume (3M)1.75M
Market Cap
kr107.90M
Enterprise Valuekr371.41M
Total Cash (Recent Filing)kr33.89M
Total Debt (Recent Filing)kr689.00K
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding133,535,460
10 Day Avg. Volume1,883,755
30 Day Avg. Volume1,753,338
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.67
Price to Sales (P/S)0.00
P/FCF Ratio-5.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.25
Revenue Forecast (FY)kr89.63M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low financial leverage (debt-to-equity ~0.01) reduces interest burden and refinancing pressure, giving management more time to advance clinical programs. This structural balance-sheet strength supports strategic optionality and flexibility across upcoming development or partnering choices.
Targeted Lead AssetOrviglance addresses a defined clinical niche—liver MRI where gadolinium is unsuitable—creating a differentiated market opportunity. A successful approval would translate into a focused commercial pathway and sustainable demand from clinicians seeking safer contrast options for specific patient subsets.
Improving Cash Burn TrendManagement reports cash burn improved materially versus 2022–2023, signaling progress in trimming operating outflows. A durable downward trend in burn extends runway, lowers near-term financing needs, and increases the probability management can reach key development milestones without immediate dilutive capital raises.
Bears Say
No RevenueThe company remains a development-stage firm with no revenue across recent periods. Absence of commercial cash inflows means long-term viability depends on trial success, partnerships, or financing. Without revenue, persistent reliance on external capital is a structural vulnerability for executing strategy.
Large Ongoing LossesSustained multi-year net losses (~71m TTM) reflect development costs that erode equity and limit reinvestment capacity. Continued structural unprofitability increases dilution risk from future financings and constrains the firm's ability to scale or respond to setbacks without external funding or strategic partnerships.
Balance-Sheet ConsumptionDeclining equity and assets with deeply negative ROE indicate the balance sheet is being consumed by operating losses. Over several months this reduces financial resilience, heightens runway risk, and increases sensitivity to adverse trial outcomes or regulatory delays absent new capital or a commercialization inflection.
Ascelia Pharma AB News
ACE FAQ
What was Ascelia Pharma AB’s price range in the past 12 months?
Ascelia Pharma AB lowest stock price was kr0.70 and its highest was kr5.23 in the past 12 months.
What is Ascelia Pharma AB’s market cap?
Ascelia Pharma AB’s market cap is kr107.90M.
When is Ascelia Pharma AB’s upcoming earnings report date?
Ascelia Pharma AB’s upcoming earnings report date is Aug 20, 2026 which is in 45 days.
How were Ascelia Pharma AB’s earnings last quarter?
Ascelia Pharma AB released its earnings results on May 12, 2026. The company reported -kr0.129 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.129.
Is Ascelia Pharma AB overvalued?
According to Wall Street analysts Ascelia Pharma AB’s price is currently Overvalued.
Does Ascelia Pharma AB pay dividends?
Ascelia Pharma AB does not currently pay dividends.
What is Ascelia Pharma AB’s EPS estimate?
Ascelia Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ascelia Pharma AB have?
Ascelia Pharma AB has 133,535,460 shares outstanding.
What happened to Ascelia Pharma AB’s price movement after its last earnings report?
Ascelia Pharma AB reported an EPS of -kr0.129 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.372%.
Which hedge fund is a major shareholder of Ascelia Pharma AB?
Currently, no hedge funds are holding shares in SE:ACE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ascelia Pharma AB
Ascelia Pharma AB (publ) is a Swedish biotechnology company concentrating on the development of orphan drugs for cancer treatment. The firm is currently progressing Mangoral, an innovative non-gadolinium contrast agent, through Phase 3 clinical trials for magnetic resonance imaging (MRI) of the liver. Furthermore, it is advancing Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 development for gastric cancer therapy. Ascelia Pharma has also entered into a clinical collaboration agreement with Taiho Oncology, Inc. to develop Oncoral in combination with LONSURF. The company was established in 2000 and has its headquarters situated in Malmö, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Isofol Medical AB
―
Guard Therapeutics International AB
―
Immunicum AB
―
Cantargia AB
―